Table 2.

Characteristics of the 16 patients who received neratinib (N, %)a

Age, years
 Median (range)58 (31–74)
Race
 White/African American/Asian13 (81%)/1 (6%)/2 (13%)
ECOG PS
 0/1/29 (56%)/7 (44%)/0 (0%)
Menopausal status
 Pre-/postmenopausal2 (12%)/14(88%)
Histology
 Ductal/lobular11 (67%)/5 (31.3%)
Hormone receptor status
 ER+PR+/ER+PR/ERPRHER27 (44%)/8 (50%)/1 (6%)
HER2 status
 Nonamplified/amplified16 (100%)/0 (0%)
Evaluable disease by RECIST
 Measurable/nonmeasurable13 (81%)/3 (19%)
Disease magnitude
 Visceral/nonvisceral11 (69%)/5 (31%)
Prior number of metastatic regimens
 Any/endocrine/chemo (median, range)3 (2–10)/2 (0–3)/2 (0–6)
Reason off study
 Adverse event/progressive disease1 (6%)/15 (94%)
  • aUnless otherwise specified.